Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> CMBI Slightly Raises TP for INNOVENT BIO (01801.HK) to HKD113.86, Accelerating Global Biopharmaceutical Transformation
Recommend 3 Positive 2 Negative 4 |
||||
|
||||
|
CMBI published a research report indicating that INNOVENT BIO (01801.HK) showed strong performance in the fiscal year 2025, recording its first full-year net profit of RMB834 million. During the period, total revenue reached RMB13 billion, representing a year-on-year increase of 38%; product sales amounted to RMB11.9 billion, a year-on-year increase of 45%. Given INNOVENT BIO's strong product line innovation capabilities and global development potential, accelerating its transformation into a global biopharmaceutical company, CMBI maintains a "Buy" rating on INNOVENT BIO, with the target price slightly raised from HKD110.62 to HKD113.86. (hc/da) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
